Latest news
AbCellera Stock Soars 30% After Menopause Drug ABCL635 Hits Phase 2 Success In Hot Flash Trial Results - International Business Times AustraliaInternational Business Times Australia · Mon, 10 Aug 2026 13:44:13 GMTStockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss - Genetic Engineering and Biotechnology NewsGenetic Engineering and Biotechnology News · Mon, 10 Aug 2026 04:37:02 GMTIovance Biotherapeutics Stock Soars 34% After Record $99 Million Quarter Beats Wall Street Estimates - International Business Times AustraliaInternational Business Times Australia · Thu, 06 Aug 2026 13:38:58 GMTKrystal Biotech (KRYS) After Its Q2 Beat Is The Valuation Case Still Intact - SahmSahm · Wed, 05 Aug 2026 07:00:00 GMTNeuren Pharmaceuticals Stock Soars 17.5% After Record DAYBUE Sales Growth and Royalty Forecast Boost - International Business Times AustraliaInternational Business Times Australia · Wed, 05 Aug 2026 06:18:02 GMTKrystal Biotech Earnings Call Signals Profitable Growth - TipRanksTipRanks · Wed, 05 Aug 2026 03:31:43 GMTKRYS SWOT Analysis: Strong Revenue Growth and Market Potential R - GuruFocusGuruFocus · Tue, 04 Aug 2026 08:53:36 GMTIs Krystal Biotech (KRYS) Overvalued After Q2 Earnings Beat? EPS of $1.85 & Revenue of $119.2M; GF Score: 54/100 - GuruFocusGuruFocus · Tue, 04 Aug 2026 00:00:00 GMT